Viva Ventures Biotech Fund

Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.

Jiaxing Tecolo Biotechnology Co., Ltd. (hereinafter “Tecolo”), which focuses on developing new skin drugs, announced that it recently completed an A+ financing round worth tens of millions of yuan. The company received support in this round from Chengdu Biocity No. 1 Equity Investment Fund and Chengdu Hi-Tech New Economy Venture Capital Co., Ltd.

As a world-leading one-stop platform for drug R&D and production services, Viva Biotech was awarded "Top 20 Chinese R&D CRO Enterprises in 2022" and placed sixth on the list. Additionally, Viva's subsidiary, Langhua Pharmaceutical, was recognized as one of the "Top 20 Chinese CDMO Enterprises in 2022".

TEL AVIV, Israel and SHANGHAI, Jan. 6, 2023 -- VivaVision, a pharmaceutical company developing innovative therapies for ocular diseases, and Everads Therapy, a biotech company developing optimized retinal therapies by leveraging its novel suprachoroidal delivery technology, announced today that they are partnering to develop safer, more effective, and more durable treatments for retinal diseases.

Viva Ventures Biotech Fund invests in early stage, first-in-class, drug discovery startups in large scale. We have partnered with a team of renowned entrepreneurial scientists to deliver high returns with minimal risk to qualified investors. More about us：www.vivaventuresbiotech.com